DZ2729A1 - Composés nouveaux inhibiteurs de nhe-1 procédé pour leur préparation et compositions pharmaceutiquesles contenant. - Google Patents

Composés nouveaux inhibiteurs de nhe-1 procédé pour leur préparation et compositions pharmaceutiquesles contenant.

Info

Publication number: DZ2729A1
Authority: DZ; Algeria
Prior art keywords: nhe; preparation; pharmaceutical compositions; compositions containing; new inhibitors
Prior art date: 1998-02-27

Application number

DZ990032A

Other languages

English (en)

French (fr)

Inventor

Ernest S Hamanaka

Guzman Perez Angel

Roger B Ruggeri

Ronald T Wester

Christian J Mularski

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-02-27

Filing date

1999-02-24

Publication date

2005-03-01

1999-02-24 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2005-03-01 Application granted granted Critical

2005-03-01 Publication of DZ2729A1 publication Critical patent/DZ2729A1/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Surgery (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Plural Heterocyclic Compounds (AREA)
Steroid Compounds (AREA)

DZ990032A 1998-02-27 1999-02-24 Composés nouveaux inhibiteurs de nhe-1 procédé pour leur préparation et compositions pharmaceutiquesles contenant. DZ2729A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US7636298P	1998-02-27	1998-02-27

Publications (1)

Publication Number	Publication Date
DZ2729A1 true DZ2729A1 (fr)	2005-03-01

Family

ID=22131525

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DZ990032A DZ2729A1 (fr)	1998-02-27	1999-02-24	Composés nouveaux inhibiteurs de nhe-1 procédé pour leur préparation et compositions pharmaceutiquesles contenant.

Country Status (39)

Country	Link
US (2)	US6492401B1 (xx)
EP (2)	EP1454902A1 (xx)
JP (2)	JP2002504546A (xx)
KR (4)	KR20030083004A (xx)
CN (1)	CN1289326A (xx)
AP (1)	AP9901478A0 (xx)
AR (1)	AR015526A1 (xx)
AT (1)	ATE286034T1 (xx)
AU (1)	AU739403B2 (xx)
BG (1)	BG104803A (xx)
BR (1)	BR9908332A (xx)
CA (1)	CA2321642A1 (xx)
CO (1)	CO4980897A1 (xx)
DE (1)	DE69922930T2 (xx)
DK (1)	DK1056729T3 (xx)
DZ (1)	DZ2729A1 (xx)
EA (1)	EA003603B1 (xx)
ES (1)	ES2237080T3 (xx)
GT (1)	GT199900022A (xx)
HR (2)	HRP20000550A2 (xx)
HU (1)	HUP0204418A3 (xx)
ID (1)	ID25505A (xx)
IL (1)	IL136588A0 (xx)
IS (1)	IS5548A (xx)
NO (1)	NO20004192L (xx)
NZ (1)	NZ504769A (xx)
OA (1)	OA11450A (xx)
PA (1)	PA8468401A1 (xx)
PE (1)	PE20000334A1 (xx)
PL (1)	PL342444A1 (xx)
PT (1)	PT1056729E (xx)
SI (1)	SI1056729T1 (xx)
SK (1)	SK12342000A3 (xx)
TN (1)	TNSN99028A1 (xx)
TR (1)	TR200002480T2 (xx)
TW (1)	TWI226329B (xx)
WO (1)	WO1999043663A1 (xx)
YU (1)	YU46200A (xx)
ZA (1)	ZA991578B (xx)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20030083004A (ko) *	1998-02-27	2003-10-23	화이자 프로덕츠 인크.	허혈 치료용 ｎ-[(치환된 5원 디아자 이불포화고리)카르보닐] 구아니딘 유도체
FR2795726A1 (fr) *	1999-06-30	2001-01-05	Aventis Cropscience Sa	Nouveaux pyrazoles fongicides
US6441176B1 (en)	1999-10-29	2002-08-27	Pfizer Inc.	Method for preparing sodium-hydrogen exchanger type 1 inhibitor
UA72002C2 (en) *	1999-10-29	2005-01-17	Pfizer Prod Inc	Inhibitors crystals of sodium-hydrogen exchange of 1 type, a method for the preparation thereof (variants), a pharmaceuticalcomposition based thereon and a method for the reduction of tissue damage
YU54202A (sh)	2000-01-18	2006-01-16	Agouron Pharmaceuticals Inc.	Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es)	2000-01-21	2003-12-11	Inc Agouron Pharmaceuticals	Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
US6570013B2 (en)	2000-02-16	2003-05-27	Pfizer Inc	Salts of zopolrestat
US6555569B2 (en) *	2000-03-07	2003-04-29	Pfizer Inc.	Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection
US6395767B2 (en)	2000-03-10	2002-05-28	Bristol-Myers Squibb Company	Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
BR0110302A (pt)	2000-04-18	2003-01-14	Agouron Pharma	Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase
AU2001235896A1 (en) *	2000-04-28	2001-11-12	Pfizer Products Inc.	Sodium-hydrogen exchanger type 1 inhibitor (nhe-1)
US6852733B2 (en)	2000-04-28	2005-02-08	Pfizer Inc.	Sodium-hydrogen exchanger type 1 inhibitor
IL144507A0 (en) *	2000-07-31	2002-05-23	Pfizer Prod Inc	Use of glycogen phosphorylase inhibitors to inhibit tumor growth
MXPA03004783A (es) *	2000-11-28	2003-09-10	Pfizer Prod Inc	Preparacion de inhibidores del intercambiador de sodio-huidrogeno de tipo 1.
US6423705B1 (en)	2001-01-25	2002-07-23	Pfizer Inc.	Combination therapy
IL147696A0 (en) *	2001-01-25	2002-08-14	Pfizer Prod Inc	Combination therapy
JP2004518686A (ja) *	2001-01-31	2004-06-24	ファイザー・プロダクツ・インク	ナトリウム−水素交換輸送体１型阻害剤のエタノラート
WO2002098429A1 (en) *	2001-06-07	2002-12-12	Pfizer Products Inc.	Ethanolamine, diethanolamine or triethanolamine salt of zopolrestat
US7358267B2 (en) *	2001-06-29	2008-04-15	Amgen Inc.	Bis-aryl thiazole derivatives
KR20050042225A (ko) *	2001-11-02	2005-05-06	아벤티스 파마슈티칼스 인크.	아데노신 ａ1/ａ2 효능제 및 나트륨 수소 교환 억제제를포함하는 약제학적 조성물
AU2002337460A1 (en)	2001-12-19	2003-06-30	Pfizer Products Inc.	Methods for preparing sodium-hydrogen exchanger type-1 inhibitors
WO2003064409A1 (en) *	2002-01-30	2003-08-07	Pfizer Products Inc.	Zoniporide mesylate pharmaceutical compositions and processes for improving solubility of zoniporide
CA2483927A1 (en) *	2002-05-02	2003-11-13	Pfizer Products Inc.	Treatment of diabetes and diabetic complications with nhe-1 inhibitors
US7057046B2 (en)	2002-05-20	2006-06-06	Bristol-Myers Squibb Company	Lactam glycogen phosphorylase inhibitors and method of use
FR2840302B1 (fr) *	2002-06-03	2004-07-16	Aventis Pharma Sa	Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
FR2842525B1 (fr) *	2002-07-16	2005-05-13	Aventis Pharma Sa	Derives de 3-guanidinocarbonyl-1-heteroaryl-indole, procede de preparation a titre de medicaments et compositions pharmaceutiques les renfermant
FR2842526B1 (fr) *	2002-07-16	2007-07-13	Aventis Pharma Sa	Compositions pharmaceutiques contenant un derive de 3-guanidinocarbonyl-1-heteroaryl-indole, procede de preparation a titre de medicaments
FR2842524B1 (fr) *	2002-07-16	2005-04-22	Aventis Pharma Sa	Compositions pharmaceutiques contenant un derive de 3-guanidinocarbonyl-1-heteroaryl-pyrrole, leur procede de preparation a titre de medicaments
DE60329030D1 (de) *	2002-12-04	2009-10-08	Ore Pharmaceuticals Inc	Melanocortin-rezeptormodulatoren
CN100436445C (zh) *	2003-02-07	2008-11-26	第一制药株式会社	吡唑衍生物
US7576121B2 (en)	2003-11-12	2009-08-18	Phenomix Corporation	Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7317109B2 (en)	2003-11-12	2008-01-08	Phenomix Corporation	Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
EP1743676A1 (en)	2003-11-12	2007-01-17	Phenomix Corporation	Heterocyclic boronic acid derivatives, dipeptidyl peptidase IV inhibitors
TW200526641A (en) *	2003-12-26	2005-08-16	Daiichi Seiyaku Co	Amidopyrazole derivatives
WO2005079803A1 (en) *	2004-02-13	2005-09-01	Pfizer Products, Inc.	Compounds for treatment of cardiovascular diseases
JP2008505975A (ja)	2004-07-12	2008-02-28	フェノミックスコーポレーション	制約されたシアノ化合物
WO2006055462A1 (en)	2004-11-15	2006-05-26	Bristol-Myers Squibb Company	2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7214704B2 (en)	2004-11-15	2007-05-08	Bristol-Myers Squibb Company	2-Amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7365061B2 (en)	2004-11-15	2008-04-29	Bristol-Myers Squibb Company	2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055435A1 (en)	2004-11-15	2006-05-26	Bristol-Myers Squibb Company	2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
ES2387682T3 (es) *	2005-01-10	2012-09-28	Debiopharm S.A.	Utilización de un undecapéptido cíclico para la preparación de un medicamento administrable durante situaciones isquémicas miocárdicas
US20060235028A1 (en)	2005-04-14	2006-10-19	Li James J	Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
US7825139B2 (en)	2005-05-25	2010-11-02	Forest Laboratories Holdings Limited (BM)	Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US8318941B2 (en)	2006-07-06	2012-11-27	Bristol-Myers Squibb Company	Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US7727978B2 (en)	2006-08-24	2010-06-01	Bristol-Myers Squibb Company	Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
EP2142551B1 (en)	2007-04-17	2015-10-14	Bristol-Myers Squibb Company	Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type i inhibitors
EP2173717B9 (en)	2007-07-27	2013-06-26	Bristol-Myers Squibb Company	Novel glucokinase activators and methods of using same
CN102076680B (zh)	2008-04-28	2016-03-02	詹森药业有限公司	作为脯氨酰羟化酶抑制剂的苯并咪唑
US10517839B2 (en)	2008-06-09	2019-12-31	Cornell University	Mast cell inhibition in diseases of the retina and vitreous
BRPI0921097B8 (pt) *	2008-11-21	2021-05-25	Raqualia Pharma Inc	composto ou seu sal farmaceuticamente aceitável, intermediário do composto, composição farmacêutica e uso do composto
WO2010094090A2 (en) *	2009-02-18	2010-08-26	Katholleke Universiteit Leuven	Synucleinopathies
WO2011130459A1 (en)	2010-04-14	2011-10-20	Bristol-Myers Squibb Company	Novel glucokinase activators and methods of using same
CN102408385B (zh) *	2011-06-20	2014-06-18	雅本化学股份有限公司	一种2-取代-2h-1,2,3-三氮唑衍生物的制备方法
CN102408386B (zh) *	2011-07-27	2014-05-07	雅本化学股份有限公司	2,4-二取代-2h-1,2,3-三氮唑衍生物的制备方法
CN103929964A (zh)	2011-09-23	2014-07-16	拜耳知识产权有限责任公司	4-取代的1-苯基吡唑-3-甲酸衍生物作为对抗非生物植物胁迫的活性物质的用途
EP3091009B1 (en)	2011-10-25	2018-08-29	Janssen Pharmaceutica NV	Meglumine salt formulations of 1-(5,6-dichloro-1h-benzo[d]imidazol-2-yl)-1h-pyrazole-4-carboxylic acid
EP2819675A4 (en)	2012-02-27	2015-07-22	Essentialis Inc	SALTS OF KALIUM ATP CHANNEL OPENERS AND USES THEREOF
CA2994924A1 (en)	2015-08-06	2017-02-09	Ube Industries, Ltd.	Substituted guanidine derivatives
WO2017057695A1 (ja) *	2015-09-30	2017-04-06	東レ株式会社	ジフェニルピラゾール誘導体及びその医薬用途
TWI758751B (zh)	2015-12-16	2022-03-21	日商日本曹達股份有限公司	芳基唑化合物及有害生物防除劑
US10344002B2 (en)	2016-09-26	2019-07-09	Nusirt Sciences, Inc.	Compositions and methods for treating metabolic disorders
CN108017584B (zh) *	2017-06-20	2021-03-23	南开大学	A3腺苷受体的小分子拮抗剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2104931B1 (xx) *	1970-09-08	1975-01-10	Ferlux
CA2121391A1 (en)	1993-04-28	1994-10-29	Atsuyuki Kojima	Indoloylguanidine derivatives
IL109570A0 (en) *	1993-05-17	1994-08-26	Fujisawa Pharmaceutical Co	Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
EP0639573A1 (de) *	1993-08-03	1995-02-22	Hoechst Aktiengesellschaft	Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament
US5852046A (en)	1993-08-03	1998-12-22	Hoechst Aktiengesellschaft	Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them
DE4412334A1 (de)	1994-04-11	1995-10-19	Hoechst Ag	Substituierte N-Heteroaroylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
CA2160600A1 (en)	1994-10-18	1996-04-19	Masahumi Kitano	Indoloylguanidine derivatives
NZ314105A (en)	1996-02-02	1997-12-19	Sumitomo Pharma	Guanidine derivative substituted with a substituted indole which is peri condensed with a heterocyclic ring
JPH09291076A (ja) *	1996-04-24	1997-11-11	Sumitomo Pharmaceut Co Ltd	置換グアニジン誘導体およびその製法
AR009435A1 (es) *	1996-12-16	2000-04-12	Yamanouchi Pharma Co Ltd	Derivado de guanaidina n-[carbonil(heteroaril-substituida de 5 miembros)], un inhibidor del intercambiador de na+/h+ que comprende dicho derivado y usosen la fabricacion de medicamentos.
KR20030083004A (ko) *	1998-02-27	2003-10-23	화이자 프로덕츠 인크.	허혈 치료용 ｎ-[(치환된 5원 디아자 이불포화고리)카르보닐] 구아니딘 유도체

1999
- 1999-02-05 KR KR10-2003-7012300A patent/KR20030083004A/ko not_active Application Discontinuation
- 1999-02-05 NZ NZ504769A patent/NZ504769A/en unknown
- 1999-02-05 CA CA002321642A patent/CA2321642A1/en not_active Abandoned
- 1999-02-05 YU YU46200A patent/YU46200A/sh unknown
- 1999-02-05 KR KR10-2000-7009529A patent/KR100449600B1/ko not_active IP Right Cessation
- 1999-02-05 EA EA200000789A patent/EA003603B1/ru not_active IP Right Cessation
- 1999-02-05 AU AU20706/99A patent/AU739403B2/en not_active Ceased
- 1999-02-05 KR KR10-2002-7017553A patent/KR100407903B1/ko not_active IP Right Cessation
- 1999-02-05 ID IDW20001633A patent/ID25505A/id unknown
- 1999-02-05 EP EP04008203A patent/EP1454902A1/en not_active Withdrawn
- 1999-02-05 DK DK99901083T patent/DK1056729T3/da active
- 1999-02-05 WO PCT/IB1999/000206 patent/WO1999043663A1/en not_active Application Discontinuation
- 1999-02-05 SI SI9930743T patent/SI1056729T1/xx unknown
- 1999-02-05 ES ES99901083T patent/ES2237080T3/es not_active Expired - Lifetime
- 1999-02-05 PT PT99901083T patent/PT1056729E/pt unknown
- 1999-02-05 HU HU0204418A patent/HUP0204418A3/hu not_active Application Discontinuation
- 1999-02-05 DE DE69922930T patent/DE69922930T2/de not_active Expired - Fee Related
- 1999-02-05 AT AT99901083T patent/ATE286034T1/de not_active IP Right Cessation
- 1999-02-05 TR TR2000/02480T patent/TR200002480T2/xx unknown
- 1999-02-05 KR KR10-2003-7009644A patent/KR20030078886A/ko not_active Application Discontinuation
- 1999-02-05 JP JP2000533420A patent/JP2002504546A/ja active Pending
- 1999-02-05 BR BR9908332-9A patent/BR9908332A/pt not_active IP Right Cessation
- 1999-02-05 PL PL99342444A patent/PL342444A1/xx not_active Application Discontinuation
- 1999-02-05 CN CN99802628A patent/CN1289326A/zh active Pending
- 1999-02-05 SK SK1234-2000A patent/SK12342000A3/sk unknown
- 1999-02-05 IL IL13658899A patent/IL136588A0/xx unknown
- 1999-02-05 EP EP99901083A patent/EP1056729B1/en not_active Expired - Lifetime
- 1999-02-05 US US09/367,731 patent/US6492401B1/en not_active Expired - Fee Related
- 1999-02-22 GT GT199900022A patent/GT199900022A/es unknown
- 1999-02-22 TW TW088102574A patent/TWI226329B/zh active
- 1999-02-23 PE PE1999000156A patent/PE20000334A1/es not_active Application Discontinuation
- 1999-02-24 TN TNTNSN99028A patent/TNSN99028A1/fr unknown
- 1999-02-24 DZ DZ990032A patent/DZ2729A1/xx active
- 1999-02-24 PA PA19998468401A patent/PA8468401A1/es unknown
- 1999-02-25 AR ARP990100791A patent/AR015526A1/es unknown
- 1999-02-25 AP APAP/P/1999/001478A patent/AP9901478A0/en unknown
- 1999-02-26 ZA ZA9901578A patent/ZA991578B/xx unknown
- 1999-03-01 CO CO99012526A patent/CO4980897A1/es unknown
2000
- 2000-06-27 IS IS5548A patent/IS5548A/is unknown
- 2000-08-18 OA OA1200000223A patent/OA11450A/en unknown
- 2000-08-22 NO NO20004192A patent/NO20004192L/no not_active Application Discontinuation
- 2000-08-24 HR HR20000550A patent/HRP20000550A2/hr not_active Application Discontinuation
- 2000-09-27 BG BG104803A patent/BG104803A/bg unknown
2001
- 2001-08-29 HR HR20010666A patent/HRP20010666A2/hr not_active Application Discontinuation
2002
- 2002-12-09 US US10/315,369 patent/US6974813B2/en not_active Expired - Fee Related
2004
- 2004-08-27 JP JP2004248129A patent/JP2005041879A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
KR20030009548A (ko)	2003-01-29
YU46200A (sh)	2003-02-28
SK12342000A3 (sk)	2001-03-12
PE20000334A1 (es)	2000-05-13
IL136588A0 (en)	2001-06-14
AP9901478A0 (en)	1999-03-31
ATE286034T1 (de)	2005-01-15
US20030149043A1 (en)	2003-08-07
PA8468401A1 (es)	2000-09-29
DE69922930D1 (de)	2005-02-03
HRP20010666A2 (en)	2001-10-31
EA200000789A1 (ru)	2001-02-26
EP1454902A1 (en)	2004-09-08
AU2070699A (en)	1999-09-15
HUP0204418A2 (hu)	2003-04-28
BR9908332A (pt)	2000-11-07
WO1999043663A1 (en)	1999-09-02
BG104803A (bg)	2001-05-31
EP1056729A1 (en)	2000-12-06
JP2002504546A (ja)	2002-02-12
OA11450A (en)	2003-12-04
TR200002480T2 (tr)	2000-12-21
ZA991578B (en)	2000-08-28
PT1056729E (pt)	2005-04-29
IS5548A (is)	2000-06-27
NO20004192D0 (no)	2000-08-22
HUP0204418A3 (en)	2003-10-28
KR20030083004A (ko)	2003-10-23
ID25505A (id)	2000-10-05
AR015526A1 (es)	2001-05-02
NO20004192L (no)	2000-08-22
CA2321642A1 (en)	1999-09-02
US6492401B1 (en)	2002-12-10
KR20010041397A (ko)	2001-05-15
ES2237080T3 (es)	2005-07-16
JP2005041879A (ja)	2005-02-17
AU739403B2 (en)	2001-10-11
CO4980897A1 (es)	2000-11-27
HRP20000550A2 (en)	2001-02-28
US6974813B2 (en)	2005-12-13
EA003603B1 (ru)	2003-06-26
PL342444A1 (en)	2001-06-04
TWI226329B (en)	2005-01-11
CN1289326A (zh)	2001-03-28
KR100407903B1 (ko)	2003-12-01
EP1056729B1 (en)	2004-12-29
DE69922930T2 (de)	2005-12-29
TNSN99028A1 (fr)	2005-11-10
KR20030078886A (ko)	2003-10-08
DK1056729T3 (da)	2005-04-11
SI1056729T1 (en)	2005-04-30
NZ504769A (en)	2005-04-29
KR100449600B1 (ko)	2004-09-21
GT199900022A (es)	2000-08-15

Publication	Publication Date	Title
DZ2729A1 (fr)	2005-03-01	Composés nouveaux inhibiteurs de nhe-1 procédé pour leur préparation et compositions pharmaceutiquesles contenant.
DZ3052A1 (fr)	2004-03-27	Composés nouveaux inhibiteurs de métalloprotéases,procédé pour leur préparation et compositions pha rmaceutiques les contenant.
CY2537B1 (fr)	2006-06-28	Composés hétérocycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant
DZ2753A1 (fr)	2005-09-15	Hydroxamides d'acides (4-arylsulfonylamino)-tétrahydropyranne-4-carboxyliques) procédé pour leur préparation et compositions les contenant.
DZ2128A1 (fr)	2002-10-26	Composés nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2962A1 (fr)	2004-03-15	Dérivés de 3-azabicycloÄ3,1,0Ühexane nouveaux, procédé pour leur préparation et compositions les contenant.
DZ2465A1 (fr)	2003-01-18	Pyrazolopyrimidinones nouvelles procédé pour leur préparation et compositions les contenant.
DZ2360A1 (fr)	2002-12-28	Dérivés de pyrazole procédé pour leur préparation et compositions les contenant
DZ2891A1 (fr)	2003-12-15	Dérivés de tétrahydroquinoléines substués nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ3016A1 (fr)	2004-03-20	Composés nouveaux inhibiteurs de réabsorption de monoamines, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2889A1 (fr)	2003-12-15	4-Carboxyamino-2-méthyl-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositionspharmaceutiques les contenant.
DZ2440A1 (fr)	2003-01-11	Atropisomères de 3-aryl-4(3h)-quinazolinones procédé pour leur préparation et compositions les contenant.
DZ2758A1 (fr)	2003-09-15	Dérivés bicycliques d0acide hydroxamique nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2963A1 (fr)	2004-03-15	Dérivés de bicycliques substituées nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ3038A1 (fr)	2004-03-27	Modulateurs nouveaux des récepteurs de glucocorticoïdes, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ1889A1 (fr)	2002-02-17	Dérivés de quinoléine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2773A1 (fr)	2003-12-01	Pyrazolopyrimidinones nouvelles procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2745A1 (fr)	2003-09-08	BicycloÄ2.2.1Üheptanes nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2890A1 (fr)	2003-12-15	4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2777A1 (fr)	2003-12-01	Dérivés de quinazolinamines nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2866A1 (fr)	2003-12-01	1-Aryl-3-arylméthyl-1,8-naphtyridine-4-(1H)-ones nouvelles, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2581A1 (fr)	2003-02-22	Dérivés d'acides aryloxyarylsulfonylaminohydroxamiques procédé pour leur préparation et compositionspharmaceutiques les contenant.
DZ2394A1 (fr)	2003-06-04	Dérivés de quinoléine et dérivés de quinazoline nouveax procédé pour leur préparation et compositions pharmaceutiques les contenant
DZ1957A1 (fr)	2002-02-17	Dérivés de pipéridine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26611A1 (fr)	2004-12-20	Composes heterocycliques nouveaux inhibiteurs de romatases, procede pour leur preparation et compositions pharmaceutiques les contenant